A drug used with rituximab to treat chronic lymphocytic leukemia that has come back. It is also being studied in the treatment of other types of cancer. Idelalisib blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called Zydelig. US Brand Name(s): Zydelig. FDA Approved:Yes
Are you looking for or in search of FDA approved “Idelalisib tablets in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Acute lymphoblastic leukemia treatment. Need Access of “Idelalisib tablets, get in touch with our healthcare professional.
Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions. It appears to be effective and leads to improvement of lymphadenopathy and splenomegaly. However, the lymphocyte counts take longer to decrease to normal levels with idelalisib. It is not recommended as a first-line treatment.
It is also approved for the treatment of follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), both in patients who have received at least two prior systemic therapies.
Idelalisib is approved to treat: Chronic lymphocytic leukemia (CLL) that has relapsed (come back). It is used with rituximab in patients who may be treated with rituximab alone due to other health problems.